{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:08:43Z","timestamp":1783465723538,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.antiviral.2020.104806","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T02:08:58Z","timestamp":1586916538000},"page":"104806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model"],"prefix":"10.1016","volume":"178","author":[{"given":"Martin","family":"Laure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Koch-Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Quernheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pleschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104806_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2009.11.003","article-title":"Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season","volume":"47","author":"Baranovich","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2020.104806_bib2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3389\/fmicb.2019.01327","article-title":"Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and Middle East respiratory syndrome coronavirus infections","volume":"10","author":"Behzadi","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104806_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104806_bib4","doi-asserted-by":"crossref","first-page":"28411","DOI":"10.1074\/jbc.R110.117531","article-title":"Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms","volume":"285","author":"Boivin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104806_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1506.081357","article-title":"Oseltamivir- and amantadine-resistant influenza viruses A (H1N1)","volume":"15","author":"Cheng","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104806_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2020.104806_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jmv.23986","article-title":"Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs","volume":"87","author":"Correia","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104806_bib8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","article-title":"Oseltamivir resistance during treatment of influenza A (H5N1) infection","volume":"353","author":"de Jong","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104806_bib9","article-title":"Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104806_bib10","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","article-title":"Rates of spontaneous mutation among RNA viruses","volume":"90","author":"Drake","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2020.104806_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib12","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2020.104806_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104806_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2017.03.024","article-title":"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo","volume":"142","author":"Haasbach","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.antiviral.2011.07.006","article-title":"Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses","volume":"91","author":"Haasbach","year":"2011","journal-title":"Antivir. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2020.104806_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/irv.12046","article-title":"Clinical use of approved influenza antivirals: therapy and prophylaxis","volume":"7","author":"Ison","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.antiviral.2020.104806_bib17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104806_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2020.104806_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104806_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.antiviral.2020.104806_bib21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104806_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.antiviral.2020.104806_bib23","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2020.104806_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-5822.2005.00678.x","article-title":"Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells","volume":"8","author":"Ludwig","year":"2006","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2020.104806_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","article-title":"MEK inhibition impairs influenza B virus propagation without emergence of resistant variants","volume":"561","author":"Ludwig","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2020.104806_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1743-422X-3-63","article-title":"New low-viscosity overlay medium for viral plaque assays","volume":"3","author":"Matrosovich","year":"2006","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2020.104806_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference","volume":"149","author":"McKimm-Breschkin","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib28","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM199510053331401","article-title":"The effectiveness of vaccination against influenza in healthy, working adults","volume":"333","author":"Nichol","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2020.104806_bib30","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1086\/507544","article-title":"Vaccines for seasonal and pandemic influenza","volume":"194","author":"Nichol","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104806_bib31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/nsmb859","article-title":"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition","volume":"11","author":"Ohren","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2020.104806_bib32","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/sj.onc.1207883","article-title":"Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice","volume":"23","author":"Olschlager","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2020.104806_bib33","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104806_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.antiviral.2013.04.008","article-title":"Development of cellular signaling pathway inhibitors as new antivirals against influenza","volume":"98","author":"Planz","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2020.104806_bib36","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","article-title":"Economic burden of seasonal influenza in the United States","volume":"36","author":"Putri","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2020.104806_bib37","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1016\/j.vaccine.2016.05.034","article-title":"Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014","volume":"34","author":"Radin","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2020.104806_bib38","doi-asserted-by":"crossref","first-page":"L86","DOI":"10.1529\/biophysj.106.084343","article-title":"A new model of weak acid permeation through membranes revisited: does Overton still rule?","volume":"90","author":"Saparov","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.antiviral.2020.104806_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2018.07.006","article-title":"The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression","volume":"157","author":"Schrader","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104806_bib40","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2174\/1381612043384439","article-title":"MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors","volume":"10","author":"Sebolt-Leopold","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.antiviral.2020.104806_bib41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/10533","article-title":"Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo","volume":"5","author":"Sebolt-Leopold","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2020.104806_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bmcl.2008.10.108","article-title":"Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?","volume":"19","author":"Tecle","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2020.104806_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/irv.12650","article-title":"Health and economic burden of influenza-associated illness in South Africa, 2013-2015","author":"Tempia","year":"2019","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.antiviral.2020.104806_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/B978-0-12-405880-4.00006-8","article-title":"Influenza virus resistance to antiviral therapy","volume":"67","author":"van der Vries","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104806_bib45","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1002\/j.1460-2075.1985.tb04004.x","article-title":"Apical and basolateral endocytosis in Madin-Darby canine kidney (MDCK) cells grown on nitrocellulose filters","volume":"4","author":"von Bonsdorff","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2020.104806_bib46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1060028019826565","article-title":"Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza","volume":"53","author":"Yang","year":"2019","journal-title":"Ann. Pharmacother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:59Z","timestamp":1759062779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":46,"alternative-id":["S0166354220302205"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104806","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104806"}}